

The Eiffel Tower is shown in a dark, semi-transparent style on the left side of the slide, set against a solid orange background.

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
**CONTROVERSIES & UPDATES
IN VASCULAR SURGERY**

JANUARY 25-27 2018
MARRIOTT RIVE GAUCHE & CONFERENCE CENTER
PARIS, FRANCE WWW.CACVS.ORG



Endoprothèse thoracique avec
système ***ACTIVE CONTROL*** :
Comment ça marche et quels bénéfices?

Pr J Picquet – CHU Angers



Disclosure

Speaker name:

Jean Picquet

- I have the following potential conflicts of interest to report:
 - Consulting
 - Employment in industry
 - Shareholder in a healthcare company
 - Owner of a healthcare company
- Other(s): **Principal Investigator** / W.L. Gore
- I do not have any potential conflict of interest



Conformable GORE® TAG® Thoracic Stent Graft



- Most Studied TEVAR Device
 - Ten clinical studies
 - Global Registry for Endovascular Aortic Treatment (GREAT)
 - Twenty years of clinical experience
 - **Designed for multiple etiologies with proven results**

A Legacy of Firsts

1998

First thoracic stent graft to receive CE Mark in Europe

2005

First thoracic stent graft approved in the U.S.

2008

First thoracic stent graft approved in Japan

2009

Next-generation thoracic stent graft receives CE Mark*

2011

Approved by FDA for treatment of aneurysms*

2012

First thoracic stent graft approved in the U.S. for isolated lesions including traumatic transections*

2013

First stent graft approved in the U.S. for acute and chronic Type B Dissections*

2016

First thoracic stent graft to reach 100,000 devices distributed

2017

First thoracic stent graft to feature a new delivery system that offers controlled, staged deployment



© 2017 W. L. Gore & Associates, Inc.



Gore® C-TAG® Outcomes



CONFORMABLE
THORACIC STENT GRAFT

Proven Long-Term Outcomes Across All Etiologies



ANEURYSM

89% FREEDOM

from device-related
reintervention

through 5-year follow-up
in Aneurysm of the Descending
Thoracic Aorta clinical study (TAG 08-03)

97% FREEDOM

from device-related
reintervention

through 2-year follow-up
in GREAT

TRAUMATIC TRANSECTION

100% FREEDOM

from device-related
reintervention

through 5-year follow-up
in Traumatic Transection
clinical study (TAG 08-02)

98% FREEDOM

from device-related
reintervention

through 2-year follow-up
in GREAT

TYPE B DISSECTION

90% dissection-related
survival



through 1-year follow-up
in Acute Complicated Type B
Dissection clinical study (TAG 08-01)

97% acute dissection-
related survival

through 1-year follow-up
in GREAT


Conformability

- The *Gore*[®] *C-TAG*[®] perfectly **conforms** to the anatomy *by design*
 - From the simplest case to the most challenging anatomies



What do we need more?


- **Control** during the deployment to achieve **predictability** and **accuracy of placement**





Deployment with lack of accuracy

Proximal

Distal




Even better proximal conformability to avoid bird beak



Even better navigability

- Facilitated with the 65 cm long GORE® DrySeal Flex Introducer Sheath






Gore® TAG® Conformable Thoracic Stent Graft with **ACTIVE CONTROL** system


- Same as Conformable GORE® TAG® Device
- Two major new features
 - 1-Staged deployment
 - 2-Proximal angulation control



Staged Deployment



Angulation Control



Gore[®] C-TAG[®] with **ACTIVE CONTROL** system

- Curved leading olive
- Intuitive deployment system
- Optional steps can be skipped
- Lockwire keeps stent graft attached to catheter throughout the procedure




Staged deployment

First step:

graft opens at **intermediate diameter**



Blood flows around the graft

The graft position still can be adjusted




Angulation control

- Optional feature
- Refines orthogonal placement of the proximal end of stent graft
- Available during intermediate and / or full diameter stages






Full deployment

- The graft is deployed exactly where chosen
- Maximal precision is achieved
- Angulation can still be adjusted or the graft is released of the catheter



Angulation control at full deployment

- Allows even better conformability if required





Conclusion



- Gore[®] C-TAG[®] has proven results
- Gore[®] C-TAG[®] with *ACTIVE CONTROL* system
 - *Enhances precision and predictability of the graft deployment*
 - *Is intuitive and easy to use*
 - *Will allow better clinical outcomes by decreasing adverse events during deployment of the grafts*

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
CONTROVERSIES & UPDATES
IN VASCULAR SURGERY

JANUARY 25-27 2018
MARRIOTT RIVE GAUCHE & CONFERENCE CENTER
PARIS, FRANCE WWW.CACYS.ORG



Thank you

